Dusa sees 2Q Levulan, Kerastick, Blu-U sales below 1Q

CarolynPritchard

SAN FRANCISCO (MarketWatch) -- Dusa Pharmaceuticals Inc.
dusa
on Wednesday said that it now expects second-quarter sales of its Levulan, Kerastick and Blu-U brand light device to be lower than those in the quarter ended March 31. The company also said, however, that it expects year-to-date revenue vs. the prior year "to reflect significant growth." In light of recent volatility, the biopharmaceutical company said it will release its sales results for the June 30 quarter in mid-July, ahead of the release of its full quarterly results, which are due out on or before Aug. 9.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information. Intraday data
delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc.
All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More
information on NASDAQ traded symbols and their current financial status. Intraday
data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM)
from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is
at least 60-minutes delayed. All quotes are in local exchange time.